BTK and B-cell chronic lymphocytic leukemia: Bruton tyrosine kinase inhibitors (BTKi) and B-cell lymphoma 2 inhibitors (BCL2i) have demonstrated efficacy in improving PFS and OS with manageable adverse effects, even among CLL patients harboring negative biological prognostic factors.